ANI Pharmaceuticals任命Henry Gosebruch为董事，Samy Shanmugam辞任董事但留任管理层

----- 0001023024-26-000071-index-headers.html -----
<SEC-DOCUMENT>0001023024-26-000071-index.html : 20260824
<SEC-HEADER>0001023024-26-000071.hdr.sgml : 20260824
<ACCEPTANCE-DATETIME>20260824070119
ACCESSION NUMBER: 0001023024-26-000071
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 13
CONFORMED PERIOD OF REPORT: 20260819
ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION: Financial Statements and Exhibits
FILED AS OF DATE: 20260824
DATE AS OF CHANGE: 20260824
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: ANI PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001023024
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
EIN: 582301143
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-31812
FILM NUMBER: 261306317
BUSINESS ADDRESS:
STREET 1: 104 CARNEGIE CENTER DRIVE SUITE 300
CITY: PRINCETON
STATE: NJ
ZIP: 08540
BUSINESS PHONE: 6097591810
MAIL ADDRESS:
STREET 1: 104 CARNEGIE CENTER DRIVE SUITE 300
CITY: PRINCETON
STATE: NJ
ZIP: 08540
FORMER COMPANY:
FORMER CONFORMED NAME: BIOSANTE PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19991228
FORMER COMPANY:
FORMER CONFORMED NAME: BEN ABRAHAM TECHNOLOGIES INC
DATE OF NAME CHANGE: 19991027
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ani-20260819.htm
<DESCRIPTION>8-K
<TEXT>
Document 1 - file: ani-20260819.htm
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>anip-20260824xexx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
Document 2 - file: anip-20260824xexx991.htm
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ani-20260819.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
Document 3 - file: ani-20260819.xsd
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ani-20260819_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
Document 4 - file: ani-20260819_lab.xml
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ani-20260819_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
Document 5 - file: ani-20260819_pre.xml
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>a1a.jpg
<TEXT>
Document 6 - file: a1a.jpg
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 8 - file: R1.htm
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 9 - file: report.css
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 10 - file: Show.js
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 12 - file: FilingSummary.html
Document 12 - RAW XML: FilingSummary.xml
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 14 - file: MetaLinks.json
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001023024-26-000071-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 15 - file: 0001023024-26-000071-xbrl.zip
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>ani-20260819_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 16 - file: ani-20260819_htm.html
Document 16 - RAW XML: ani-20260819_htm.xml
</DOCUMENT>
</SEC-DOCUMENT>

----- 0001023024-26-000071.txt -----
0001023024-26-000071.txt : 20260824
0001023024-26-000071.hdr.sgml : 20260824
20260824070119
ACCESSION NUMBER: 0001023024-26-000071
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 13
CONFORMED PERIOD OF REPORT: 20260819
ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION: Financial Statements and Exhibits
FILED AS OF DATE: 20260824
DATE AS OF CHANGE: 20260824
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: ANI PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001023024
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
EIN: 582301143
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-31812
FILM NUMBER: 261306317
BUSINESS ADDRESS:
STREET 1: 104 CARNEGIE CENTER DRIVE SUITE 300
CITY: PRINCETON
STATE: NJ
ZIP: 08540
BUSINESS PHONE: 6097591810
MAIL ADDRESS:
STREET 1: 104 CARNEGIE CENTER DRIVE SUITE 300
CITY: PRINCETON
STATE: NJ
ZIP: 08540
FORMER COMPANY:
FORMER CONFORMED NAME: BIOSANTE PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19991228
FORMER COMPANY:
FORMER CONFORMED NAME: BEN ABRAHAM TECHNOLOGIES INC
DATE OF NAME CHANGE: 19991027
8-K
1
ani-20260819.htm
8-K
ani-20260819
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM
8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported):
August 19, 2026
ANI PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-31812
58-2301143
(State or other jurisdiction of
incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
104 Carnegie Center Drive, Suite 300
Princeton
,
New Jersey
08540
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code:
(
609
)
759-1810
Not Applicable
(Former name or former address, if changed since last
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
Common Stock
ANIP
Nasdaq Stock Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company
¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 19, 2026, the Board of Directors (the “Board”) of ANI Pharmaceuticals, Inc. (the “Company”) appointed Henry Gosebruch to serve on the Board as a director with a term expiring at the Company’s 2027 annual meeting of stockholders.
Mr. Gosebruch, 53, has served as Chief Executive Officer and a member of the board of directors of Lakefront Biotherapeutics NV, a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need, since May 2025. Prior to Lakefront, Mr. Gosebruch served as President and Chief Executive Officer of Neumora Therapeutics, Inc., a publicly traded neuroscience company, from July 2023 to February 2025. Prior to Neumora, he was Executive Vice President and Chief Strategy Officer at AbbVie Inc. from December 2015 to February 2023, where his responsibilities included corporate strategy, competitive intelligence, business development, and M&A. Prior to joining Abbvie in 2015, Mr. Gosebruch spent over 20 years at J.P. Morgan, where he was Co-Head of the North American M&A Group.
There is no arrangement or understanding between Mr. Gosebruch and any other person pursuant to which Mr. Gosebruch was selected to serve as a director of the Company, nor is Mr. Gosebruch a party to any transactions required to be disclosed under Item 404(a) of Regulation S-K involving the Company. As a non-employee director, Mr. Gosebruch is eligible to participate in the ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan (the “Plan”). For his service on the Board, Mr. Gosebruch will receive compensation in accordance with the Company’s general policies for compensation of non-employee directors, including, without limitation, an initial grant of a restricted stock award under the Plan having a grant date fair value equal to $525,000 upon joining the Board, which will vest in three equal installments on the first, second and third anniversary of Mr. Gosebruch joining the Board.
On August 23, 2026, Muthusamy “Samy” Shanmugam informed the Board of his decision to resign as a director effective immediately. Mr. Shanmugam will remain in his executive management role as ANI’s Head of Research and Development and Chief Operating Officer of New Jersey Operations.
The Company issued a press release on August 24, 2026 announcing Mr. Gosebruch’s appointment to the Board and Mr. Shanmugam’s resignation. A copy of the press release is attached to this Form 8-K as Exhibit 99.1 and incorporated by reference herein.
Item 9.01
Exhibits.
(d)
Exhibits
Exhibit
No.
Description
99.1
Press Release, dated August 24, 2026
104
Cover Page Interactive Data File (embedded with the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 24, 2026
ANI PHARMACEUTICALS, INC.
By:
/s/ Stephen P. Carey
Name:
Stephen P. Carey
Title:
Senior Vice President Finance and Chief Financial Officer
EX-99.1
2
anip-20260824xexx991.htm
EX-99.1
Document
Exhibit 99.1
ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors
– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company –
PRINCETON, N.J., August 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today reported the addition of Henry Gosebruch to its Board of Directors effective August 19, 2026. Mr. Gosebruch brings over 30 years of corporate strategy, business development and finance experience across the biopharmaceutical sector.
“We are excited to add Henry to our Board of Directors during this pivotal moment for the Company,” stated Thomas (Tom) J. Haughey, Chairman of the Board of ANI. “His proven track record in corporate strategy and value-creating acquisitions is expected to strengthen our business development and capital allocation initiatives as we accelerate our transformation to become a leading Rare Disease company. We are delighted to welcome him to the Board, and look forward to his contributions,” he concluded.
“ANI has the management team, the commercial infrastructure and the balance sheet to take a meaningful next step in its evolution via additional business development,” said Mr. Gosebruch. “The Rare Disease franchise is a strong foundation, and I look forward to working with Nikhil, Tom and my fellow directors to help the Company execute the next steps in its transformation.”
Mr. Gosebruch has served as Chief Executive Officer of Lakefront Biotherapeutics NV (formerly Galapagos NV) since May 2025, where he is also a member of the Board of Directors. From July 2023 to February 2025, he served as President and Chief Executive Officer of Neumora Therapeutics, Inc., a publicly traded neuroscience company.
Prior to Neumora, from 2015 to 2023, Mr. Gosebruch was Executive Vice President and Chief Strategy Officer of AbbVie, where he built and led the company’s Corporate Strategy Office, spanning corporate strategy, competitive intelligence, business development and M&A, search and evaluation, alliance management, and AbbVie Ventures. Under his leadership, the group completed more than 100 transactions and investments, including AbbVie’s acquisition of Allergan. Earlier in his career, he spent more than 20 years at J.P. Morgan, most recently as Co-Head of North American M&A.
Mr. Gosebruch serves on the Advisory Board of the University of Pennsylvania Life Sciences & Management Program. He holds a B.S. in Economics from the Wharton School at the University of Pennsylvania and is a certified public accountant.
The Company also announced that Muthusamy (Samy) Shanmugam has notified the Board of his decision to resign as a director effective immediately. He will remain in his executive management role as ANI’s Head of Research and Development and Chief Operating Officer of New Jersey Operations.
Mr. Haughey continued, “I want to thank Samy for his dedicated Board service and valuable contributions over the past five years. We will continue to benefit from his insights and deep experience as a member of our executive leadership team.”
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives” by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit
https://www.anipharmaceuticals.com.
Forward-Looking Statements
To the extent any statements made in this release deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the Company’s strategy; its expectations regarding its future operations, financial position or revenues, including its 2026 financial guidance; its expectations regarding its share repurchase program; the results and timing of the Company’s preclinical studies, clinical trials, regulatory submissions and regulatory approvals; the commercialization and anticipated sales of the Company’s products, including current and planned product launches and any additional product launches from the Company’s generic pipeline; the Company’s estimates of the market opportunity and addressable patient populations for its products; the expansion and execution capabilities of the Company’s sales force for acute gouty arthritis for Cortrophin Gel; the Company’s anticipated growth opportunities, including for Cortrophin Gel and ILUVIEN; the Company’s positioning for continued shareholder value creation; anticipated R&D developments and clinical trial advances; and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “plans,” “potential,” “future,” “believes,” “intends,” “continue,” the negatives thereof, or other words of similar meaning, derivations of such words and the use of future dates.
Uncertainties and risks may cause the Company’s actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited to: the ability of the Company’s approved products, including Cortrophin Gel and ILUVIEN, to achieve commercialization at levels of market acceptance that will allow the Company to maintain profitability; the Company’s ability to complete or achieve any or all of the intended benefits of acquisitions and investments, in a timely manner or at all; delays and disruptions in the production of the Company’s approved products; increased costs and potential loss of revenues if the Company needs to change suppliers due to the limited number of suppliers for its raw materials, active pharmaceutical ingredients, excipients, and other materials; delays and disruptions in the production of the Company’s approved products as a result of its reliance on single source third party contract manufacturing supply for certain of its key products, including Cortrophin Gel and ILUVIEN; delays or failure to obtain or maintain approvals by the FDA of the Company’s products; changes in policy or actions that may be taken by the FDA, United States Drug Enforcement Administration and other regulatory agencies; risks that the Company may face with respect to importing raw materials and delays in delivery of raw materials and other ingredients and supplies necessary for the manufacture of the Company’s products from both domestic and overseas sources due to supply chain disruptions or for any other reason, including increased costs due to tariffs or macroeconomic disruptions; the ability of the Company’s manufacturing partners to meet its product demands and timelines; the impact of changes or fluctuations in exchange rates; the Company’s ability to develop, license or acquire, and commercialize new products; the Company’s obligations in agreements under which it licenses, develops or commercializes rights to products or technology from third parties and its ability to maintain such licenses; the level of competition the Company faces and the legal, regulatory and/or legislative strategies employed by its competitors to prevent or delay competition from generic alternatives to branded products; the Company’s ability to protect its intellectual property rights; the impact of legislative or regulatory reform on the pricing for pharmaceutical products; the impact of any litigation to which the Company is, or may become, a party; the Company’s ability, and that of its suppliers, development partners, and manufacturing partners, to comply with laws, regulations and standards that govern or affect the pharmaceutical and biotechnology industries; the Company’s ability to maintain the services of its key executives and other personnel; and general business and economic conditions, such as inflationary pressures, geopolitical conditions.
More detailed information on these and additional factors that could affect the Company’s actual results are described in the Company’s filings with the Securities and Exchange Commission (SEC), including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, and other periodic reports, as well as other filings with the SEC. All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company’s current beliefs, assumptions, and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Relations:
Irina Koffler, Vice President, Investor Relations
T: 917-734-7387
E:
Irina.koffler@anipharmaceuticals.com
Media Relations:
Argot Partners
T: 212-600-1494
E:
ani@argotpartners.com
Source: ANI Pharmaceuticals, Inc.
EX-101.SCH
3
ani-20260819.xsd
XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
0000001 - Document - Cover
link:presentationLink
link:calculationLink
link:definitionLink
EX-101.LAB
4
ani-20260819_lab.xml
XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
Soliciting Material
Soliciting Material
Written Communications
Written Communications
Local Phone Number
Local Phone Number
Cover [Abstract]
Document Period End Date
Document Period End Date
Pre-commencement Tender Offer
Pre-commencement Tender Offer
Amendment Flag
Amendment Flag
Entity Central Index Key
Entity Central Index Key
Pre-commencement Issuer Tender Offer
Pre-commencement Issuer Tender Offer
Entity Tax Identification Number
Entity Tax Identification Number
Entity Emerging Growth Company
Entity Emerging Growth Company
Entity File Number
Entity File Number
Entity Registrant Name
Entity Registrant Name
Security Exchange Name
Security Exchange Name
Trading Symbol
Trading Symbol
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Title of 12(b) Security
Title of 12(b) Security
Entity Address, State or Province
Entity Address, State or Province
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Entity Address, City or Town
Entity Address, City or Town
Entity Address, Address Line One
Entity Address, Address Line One
Document Type
Document Type
City Area Code
City Area Code
EX-101.PRE
5
ani-20260819_pre.xml
XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
GRAPHIC
6
a1a.jpg
begin 644 a1a.jpg
M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#
7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$!
M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH
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M)W$>^?Z5G54G!J.YUX*5&.(A*O\ "GJ94<[I
5#&(UW')P!CD]S[U9KWL#A(X2@J,>A\'4GSR<@K/US6+;0-&N=4O YM[
M9-[^6,MC(' _&M"N.^*C;?AIK9/_ #R4?^/K7:9G/7/QBB=
FV)F/ZG^E
5E&3_ H/5CV%
M>Y>&?!.F^'88Y%037NWY[AQDY[[1V%>A.-&DMKL^?HU,9BI.TN6)S&G#XCZW
M LXO8K&%^098D0D>PVD_GBK
IX:4?9S>OF>I:1\6RSB/6+%0O>6VSQ]5)_D:]/MYXKF".>%P\
O\\UGB:$8+FB=&6XVI5G[.IJ=%KFKG1;$7
M7]G7U\-X4QV40D<<$[L$CCC]17$O\7],^;RM-NVP<89E7!]#UKTAB I)( Y
MS7S+K-[!JGB?6=2M0/LMS=,8B!@,H 7=^.,UAAX1G+EDCLQ]:=&GSP=F>D2_
M&(#_ %6B$^[W./Y+5"?XNZL_%OI]G&3TW[G_ *BO.Z
:PT8>6WM!A8B>S$D[?3N>
M^.:S%\5^.M9C,VEZ#';VYY5G4EOP9BH/_?-:G@?P!;:#;+=7\,4FH/\ ,.,B
M(>@_VO4_Y/= 8&*\UN$7HKGT$85JD;RERK\?FSPF^\=>,;.[-M>7DUK,/^6<
MEJB$^XRO(]Q42?$7Q0AS_:6[V:&/_P")KL_C3'#_ ,(G9S,J_:4OHE@;ODAL
M@>Q .?I7D5=V'Y*D7>*/'Q_M
AZ9\6-4AF4:E:P7$/\1B&QQ^N#
M].*]5TG5+;6=/AOK1BT,JY&1@CU!]Z^9Z]M^%*2+X08OG:URY3/IA1_,&L\5
M1A&/-'0WRW%U:E3V
X![XST'>O.=8^(_A_
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M5M[&< 2.91'T(8
'6"F)S'/?G!P1U6,'@GL6/'H#UKS:
MYN;F]G\^[N9KF8_\M)I"[?3)/ ]JZ:6&E/5Z(X,5F-.B^5:L]5TWQ7X)\(6\
MMII37-R"WSO$FXN1T^9L CTQQ39_B_;*?]&TB9_^NDX3^0->4#).!7JW@[X<
M0I"E]KL*RR. T=L3P@_VO4^W:MZE*E37--W//HXK$UY
0C\@*V(=8^(-RH9-#T^%3T,S$?IOS7<6]M!:P+#;PQQ1KP$C4*
M!^ K \<>)$\+^&;F\5A]KD'DVB=VE8<<>@ZGV%
I&A52O4JO\$>0>
M.=;U36]833M7^S++I;Y*6N=F]E!Y))R0,?3)KG33(DD52TTK2SR,9)9&.2[D
MY))[T^O5I0Y8[6/E\35]K4;NVNEQT:-)(J*I9F. !W/:OHWPWI(T3P_96 P6
MBC^<^K'EOU)KRWX7Z"-0UF34IX@T%FOR;AP93T_(9/Y5[,2%3<< #J:X<74O
M+D70]O*B?"_PR+Z].M7'^JM7VPKC[TF.OX9'X_2O/H8I+B:.&)2TDC!%4
M=R3@"OH[P]I*:)H5I8*!F*,;R/XF/+'\\T8JIRQY5U%EF']I4YY;+\S5'2B@
M=*R_$&LP:!H5[JER?W=M&6QG[S?PJ/
UAZ?)3L?'8ZO[:L
MVMEHBQ8V
[GJ1]!_Z%7KW05Q8NI>7*NA[&58?D@ZCW?Y'$_%/7
MFT?PC);6[@7FI-]ECYY52/G;\%S^)%>(11+!$D2<*HP*VO&6MMXE\97=\DA:
MRM
9[LX,TQ'/4]FMH_F%>R_"W0C8Z-+J
UVUL4^Z[9D/]U!RQ_SW-?1D42Q1K&BA44
M* . *C&5++D1KE.'O)U7TV]22BBBO-/HSY2L@JV,&TY!0$_7O4]>N>(/A1:W
MM[->Z/=K8F3YFMF3,1;N5P
/%<3AE
MTN0,IR&6:/(/MAJZNVC^)YMA; K&!P)I3"6 ^O.?Q&:PQ*51IQDCMR^
WBB"VA++9V
MW= >I;U<@#Z=*[V/X9:KJ]TMWXBUDRR#H$)D8#N 3@+^ Q5CQ?\ #9KZRTNV
M\/PVL"6TK/.96(:3Y< EL')!S^=8T_9TVFW=_@=E?V]>#45RK\7Y6/)#[4=Z
M[G_A5/B'^_8_]_C_ /$TG_"JO$0_BLC_ -M3_A7H^WI_S'S_ -2Q'\C/1O 6
MFII?A"R &'N%^T2'U+
^G_]_6_^)II^%/B$=)+$_25O_B:])5Z71GSKP>);NX/^OF+\+=*C
MOO$
H/]]N ?RW5[;7EGA?PKXK\+7TD\,-E<1S)MDC:
64;/J/)Q7BGQ4\4/
MJ^L#P]:2*UA9LLETZG/F3#HF?1>I]_I7:>(8?&^M6;6EC#::5$Y^>1+LM*1Z
M!@HV_AD^XKBH_A-KZK@26"CWE;)/J?EHHQAS
1PHQ;;ZG#FG1JTDB
MHJ[F8@ >I-=P?A1X@'_+:P/TE;_XFD3X7>)(I%='L]ZG*E93P?RKTG7I_P Q
M\ZL%B+ZP9ZUH.E1:)HMK81 8BC 8C^)NI/XG-
K,MSXY;3Q#%INF1W6W:;AK@L/J$QU_'\*X6Y^&GBN_NY+
MR^N[:YNY?OS2S')]N%P![# KRXP4I7FSZ6I6E"G:E!M^FQP$,2P0I$@PJ# I
M]=S_ ,*I\0X_UMC_ -_6_P#B:0_"KQ%_?LC])3_\37J*M22LF?-O!XEN[@_Z
M^9U?PLT.*VT=M78$SW9*+_LHIQ^I'Z"O0ZX;PI8^*] M8=-N+.RN+-&XD$Y5
MD!.3VYQSQ^M=S7DUG>;=SZ?!Q4:,8VM;\PHHHK(ZSRG1_%&H74OB^'4/$TEN
M^G7DL-DJQP;BJE@!MV$N> /4UCV_B?Q=
[AN9K^:/[.F8/M2!$*E
MT)Q]XMR1C'.*[OP7X7U/P]JWB"YO9+1X]4O&ND$+L3&2S':
OM4_B?P[
MJ&L>)/#NHVKVRQ:7.\LBRLP9]V!@84]@>M %73O&]XVL:OHFI:2L6K6-L;J*
M&VF,B7"8!PK%1ALD#D?RH?QM
M7U/QEJVKQ7MM;07VG-8H5=O-CRH^;ICJ.F>AZU / FNG2?"]
MHATN%]"N4F8)(Y6XQU).P;2<>AZGGCD T1X]U"Y\47NA:=X=FN)+.ZBAFG,P
M"(C9R[<<8'0=^>F*S5^*EY<>'+S7[?0%^P6%WY%WONOG"Y494!<$_-R,\<
)_$>JW#6KQZK)')$D
M9]1NQ<),'?:@)0D'Y
#Q-H]A=:6L>G:TI-C
OPYUF/2_%&F_:+"4ZQ*94OY'
M?S@,Y",NW!''4-QDG!Z4 =#)XW2]U#2-.T*V2ZNM2M1>YG
-9O#VDW$^IZ;LO!>"SM8DE^2Y9E#*P8CY5P>
*=)A#75O:W]I=I=6@
M4%XT*C&UC@$YY.<#'''J .M/&4[:I?:?
*K7/Q#6W^'$7B\:4S)+_R[>< 5RY09;'J!V[UOQVNJ:@@34UMK9!&RNEK.
MTF\LNWDLJX R3C!YQSQSP\_P_P#$<_PZ_P"$/^TZ:L4+[H[K>Y,BB3> R[?E
MZ]06Z#US0!L7WB36U^)5IH%G9VLEJ;#[4V^
VX-N+94XY'(ZXK%F^'5[J-MXMM;^YMHXM;N%N('A9F:%E;*A@0,]LX/K0!
MT>GZOKDQTV2]TB".&^W;O)G+M;?*67?E0""!@D="0.>M8FH^/K[1K&SU#5-,
MM(+>>=8YK87>ZY@5CA7*[<'U([9'-;MI:>()M*CL;Z2SM7$)B>YM)6=F.PJ&
M564;3G#=3TQWR.*/PVUQO 4GAD7.G"07?VG[87
[;YI3'X[?3G-6[_PYK-UXZL_$$+V,:6]B]ML9V8[VR=V-HR 2.,\CTK
MU;X8W6NR:3/-%IME?VTJM=ZA:,V^X ZG9M W$\Y)X/K0!ZCMKSG3?$VJ1^-?
M&5O=74MU8Z1"LT%MM1>J[B-P7)]!DUTNE7FM/XKUBTO'M'TZ%(GMO*4AUW;O
ME;/4_+GCV]ZY^'P9K<7B#Q7J7F6!CUNW,,:>:^8CMVJ6^7GWQ0 T_$>^31M+
M\03:''%HEY,D3R&Y)FCW$C=LVX*@@]\FMV3Q/-=>+)_#^DVT4LMG");R>9RJ
MQ%A\B 98GKVP/4\5@7O@35[KX9:?X82>R%U;2(7F9VV%58L,?+G/2M6'PWJ
MFF>,K[Q#8_9)4U."-;NUEE9-DB# 9'"G(QV('6@#HM(N[F_TY)[VS-G<;W1X
M=^X JQ7(/&0<9!P."*OUBW4.OF.P-K-8JXN0UX)%8CR,G*IC^(# R<9Z\=*V
MJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
/ **** "BBB@ HHHH __9
end
XML
8
R1.htm
IDEA: XBRL DOCUMENT
Cover
Aug. 19, 2026
Cover [Abstract]
Document Type
8-K
Document Period End Date
Aug. 19, 2026
Entity Registrant Name
ANI PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code
DE
Entity File Number
001-31812
Entity Tax Identification Number
58-2301143
Entity Address, Address Line One
104 Carnegie Center Drive, Suite 300
Entity Address, City or Town
Princeton
Entity Address, State or Province
NJ
Entity Address, Postal Zip Code
08540
City Area Code
609
Local Phone Number
759-1810
Title of 12(b) Security
Common Stock
Trading Symbol
ANIP
Security Exchange Name
NASDAQ
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Entity Emerging Growth Company
false
Entity Central Index Key
0001023024
Amendment Flag
false
XML
9
report.css
IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */
/* v2.2.0.24 */
/* DefRef Styles */
.report table.authRefData{
background-color: #def;
border: 2px solid #2F4497;
font-size: 1em;
position: absolute;
}
.report table.authRefData a {
display: block;
font-weight: bold;
}
.report table.authRefData p {
margin-top: 0px;
}
.report table.authRefData .hide {
background-color: #2F4497;
padding: 1px 3px 0px 0px;
text-align: right;
}
.report table.authRefData .hide a:hover {
background-color: #2F4497;
}
.report table.authRefData .body {
height: 150px;
overflow: auto;
width: 400px;
}
.report table.authRefData table{
font-size: 1em;
}
/* Report Styles */
.pl a, .pl a:visited {
color: black;
text-decoration: none;
}
/* table */
.report {
background-color: white;
border: 2px solid #acf;
clear: both;
color: black;
font: normal 8pt Helvetica, Arial, san-serif;
margin-bottom: 2em;
}
.report hr {
border: 1px solid #acf;
}
/* Top labels */
.report th {
background-color: #acf;
color: black;
font-weight: bold;
text-align: center;
}
.report th.void {
background-color: transparent;
color: #000000;
font: bold 10pt Helvetica, Arial, san-serif;
text-align: left;
}
.report .pl {
text-align: left;
vertical-align: top;
white-space: normal;
width: 200px;
white-space: normal; /* word-wrap: break-word; */
}
.report td.pl a.a {
cursor: pointer;
display: block;
width: 200px;
overflow: hidden;
}
.report td.pl div.a {
width: 200px;
}
.report td.pl a:hover {
background-color: #ffc;
}
/* Header rows... */
.report tr.rh {
background-color: #acf;
color: black;
font-weight: bold;
}
/* Calendars... */
.report .rc {
background-color: #f0f0f0;
}
/* Even rows... */
.report .re, .report .reu {
background-color: #def;
}
.report .reu td {
border-bottom: 1px solid black;
}
/* Odd rows... */
.report .ro, .report .rou {
background-color: white;
}
.report .rou td {
border-bottom: 1px solid black;
}
.report .rou table td, .report .reu table td {
border-bottom: 0px solid black;
}
/* styles for footnote marker */
.report .fn {
white-space: nowrap;
}
/* styles for numeric types */
.report .num, .report .nump {
text-align: right;
white-space: nowrap;
}
.report .nump {
padding-left: 2em;
}
.report .nump {
padding: 0px 0.4em 0px 2em;
}
/* styles for text types */
.report .text {
text-align: left;
white-space: normal;
}
.report .text .big {
margin-bottom: 1em;
width: 17em;
}
.report .text .more {
display: none;
}
.report .text .note {
font-style: italic;
font-weight: bold;
}
.report .text .small {
width: 10em;
}
.report sup {
font-style: italic;
}
.report .outerFootnotes {
font-size: 1em;
}
XML
10
Show.js
IDEA: XBRL DOCUMENT
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
XML
12
FilingSummary.xml
IDEA: XBRL DOCUMENT
3.26.1
html
1
22
1
false
0
0
false
0
false
false
R1.htm
0000001 - Document - Cover
Sheet
http://ani.com/role/Cover
Cover
Cover
1
false
false
All Reports
Book
All Reports
ani-20260819.htm
ani-20260819.xsd
ani-20260819_lab.xml
ani-20260819_pre.xml
http://xbrl.sec.gov/dei/2025
true
false
JSON
14
MetaLinks.json
IDEA: XBRL DOCUMENT
{
"version": "2.2",
"instance": {
"ani-20260819.htm": {
"nsprefix": "ani",
"nsuri": "http://ani.com/20260819",
"dts": {
"inline": {
"local": [
"ani-20260819.htm"
]
},
"schema": {
"local": [
"ani-20260819.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
"https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
]
},
"labelLink": {
"local": [
"ani-20260819_lab.xml"
]
},
"presentationLink": {
"local": [
"ani-20260819_pre.xml"
]
}
},
"keyStandard": 22,
"keyCustom": 0,
"axisStandard": 0,
"axisCustom": 0,
"memberStandard": 0,
"memberCustom": 0,
"hidden": {
"total": 2,
"http://xbrl.sec.gov/dei/2025": 2
},
"contextCount": 1,
"entityCount": 1,
"segmentCount": 0,
"elementCount": 23,
"unitCount": 0,
"baseTaxonomies": {
"http://xbrl.sec.gov/dei/2025": 22
},
"report": {
"R1": {
"role": "http://ani.com/role/Cover",
"longName": "0000001 - Document - Cover",
"shortName": "Cover",
"isDefault": "true",
"groupType": "document",
"subGroupType": "",
"menuCat": "Cover",
"order": "1",
"firstAnchor": {
"contextRef": "c-1",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"span",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ani-20260819.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c-1",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"span",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "ani-20260819.htm",
"first": true,
"unique": true
}
}
},
"tag": {
"dei_AmendmentFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "AmendmentFlag",
"presentation": [
"http://ani.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Amendment Flag",
"label": "Amendment Flag",
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
}
}
},
"auth_ref": []
},
"dei_CityAreaCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "CityAreaCode",
"presentation": [
"http://ani.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "City Area Code",
"label": "City Area Code",
"documentation": "Area code of city"
}
}
},
"auth_ref": []
},
"dei_CoverAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "CoverAbstract",
"lang": {
"en-us": {
"role": {
"label": "Cover [Abstract]",
"documentation": "Cover page."
}
}
},
"auth_ref": []
},
"dei_DocumentPeriodEndDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "DocumentPeriodEndDate",
"presentation": [
"http://ani.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Document Period End Date",
"label": "Document Period End Date",
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
}
}
},
"auth_ref": []
},
"dei_DocumentType": {
"xbrltype": "submissionTypeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "DocumentType",
"presentation": [
"http://ani.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Document Type",
"label": "Document Type",
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
}
}
},
"auth_ref": []
},
"dei_EntityAddressAddressLine1": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityAddressAddressLine1",
"presentation": [
"http://ani.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Address, Address Line One",
"label": "Entity Address, Address Line One",
"documentation": "Address Line 1 such as Attn, Building Name, Street Name"
}
}
},
"auth_ref": []
},
"dei_EntityAddressCityOrTown": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityAddressCityOrTown",
"presentation": [
"http://ani.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Address, City or Town",
"label": "Entity Address, City or Town",
"documentation": "Name of the City or Town"
}
}
},
"auth_ref": []
},
"dei_EntityAddressPostalZipCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityAddressPostalZipCode",
"presentation": [
"http://ani.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Address, Postal Zip Code",
"label": "Entity Address, Postal Zip Code",
"documentation": "Code for the postal or zip code"
}
}
},
"auth_ref": []
},
"dei_EntityAddressStateOrProvince": {
"xbrltype": "stateOrProvinceItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityAddressStateOrProvince",
"presentation": [
"http://ani.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Address, State or Province",
"label": "Entity Address, State or Province",
"documentation": "Name of the state or province."
}
}
},
"auth_ref": []
},
"dei_EntityCentralIndexKey": {
"xbrltype": "centralIndexKeyItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityCentralIndexKey",
"presentation": [
"http://ani.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Central Index Key",
"label": "Entity Central Index Key",
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_EntityEmergingGrowthCompany": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityEmergingGrowthCompany",
"presentation": [
"http://ani.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Emerging Growth Company",
"label": "Entity Emerging Growth Company",
"documentation": "Indicate if registrant meets the emerging growth company criteria."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_EntityFileNumber": {
"xbrltype": "fileNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityFileNumber",
"presentation": [
"http://ani.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity File Number",
"label": "Entity File Number",
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
}
}
},
"auth_ref": []
},
"dei_EntityIncorporationStateCountryCode": {
"xbrltype": "edgarStateCountryItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityIncorporationStateCountryCode",
"presentation": [
"http://ani.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Incorporation, State or Country Code",
"label": "Entity Incorporation, State or Country Code",
"documentation": "Two-character EDGAR code representing the state or country of incorporation."
}
}
},
"auth_ref": []
},
"dei_EntityRegistrantName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityRegistrantName",
"presentation": [
"http://ani.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Registrant Name",
"label": "Entity Registrant Name",
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_EntityTaxIdentificationNumber": {
"xbrltype": "employerIdItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityTaxIdentificationNumber",
"presentation": [
"http://ani.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Tax Identification Number",
"label": "Entity Tax Identification Number",
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_LocalPhoneNumber": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "LocalPhoneNumber",
"presentation": [
"http://ani.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Local Phone Number",
"label": "Local Phone Number",
"documentation": "Local phone number for entity."
}
}
},
"auth_ref": []
},
"dei_PreCommencementIssuerTenderOffer": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "PreCommencementIssuerTenderOffer",
"presentation": [
"http://ani.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Pre-commencement Issuer Tender Offer",
"label": "Pre-commencement Issuer Tender Offer",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
}
}
},
"auth_ref": [
"r3"
]
},
"dei_PreCommencementTenderOffer": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "PreCommencementTenderOffer",
"presentation": [
"http://ani.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Pre-commencement Tender Offer",
"label": "Pre-commencement Tender Offer",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
}
}
},
"auth_ref": [
"r5"
]
},
"dei_Security12bTitle": {
"xbrltype": "securityTitleItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "Security12bTitle",
"presentation": [
"http://ani.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Title of 12(b) Security",
"label": "Title of 12(b) Security",
"documentation": "Title of a 12(b) registered security."
}
}
},
"auth_ref": [
"r0"
]
},
"dei_SecurityExchangeName": {
"xbrltype": "edgarExchangeCodeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "SecurityExchangeName",
"presentation": [
"http://ani.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Security Exchange Name",
"label": "Security Exchange Name",
"documentation": "Name of the Exchange on which a security is registered."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_SolicitingMaterial": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "SolicitingMaterial",
"presentation": [
"http://ani.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Soliciting Material",
"label": "Soliciting Material",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
}
}
},
"auth_ref": [
"r4"
]
},
"dei_TradingSymbol": {
"xbrltype": "tradingSymbolItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "TradingSymbol",
"presentation": [
"http://ani.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Trading Symbol",
"label": "Trading Symbol",
"documentation": "Trading symbol of an instrument as listed on an exchange."
}
}
},
"auth_ref": []
},
"dei_WrittenCommunications": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "WrittenCommunications",
"presentation": [
"http://ani.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Written Communications",
"label": "Written Communications",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
}
}
},
"auth_ref": [
"r6"
]
}
}
}
},
"std_ref": {
"r0": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b"
},
"r1": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b-2"
},
"r2": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "d1-1"
},
"r3": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "13e",
"Subsection": "4c"
},
"r4": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "14a",
"Subsection": "12"
},
"r5": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "14d",
"Subsection": "2b"
},
"r6": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "230",
"Section": "425"
}
}
}
ZIP
15
0001023024-26-000071-xbrl.zip
IDEA: XBRL DOCUMENT
begin 644 0001023024-26-000071-xbrl.zip
M4$L#!!0 ( "E8&%UP[RR$D1( =T 0 86YI+3(P,C8P.#$Y+FAT
M;>U=Z7/BQK;_GK^B'[DOXZE"0F(SX.46P7B&S'@I8)+4^W*KD1KHC)"45LO
M_>O?.=T2.V.8>,$>IZ8J@'HY^_GUZ5;[]-^3D4?NF(AXX)^]LTWK'6&^$[C<
M'YR]JW<:K=:[?Y__=/H_AO'GK^W/Y")PXA'S)6D(1B5SR9C+(9%#1OX(Q%=^
M1\FM1V4_$"/#T-T:03@5?#"4)&_ERVFS]*FH63:U['ZY8E1IU3&.[7X)/O4=
MH]3K]RM6I5BR^\7LH&;3@F7UF6.4F5LUBCVG:E!Z;!OE
8;7SJ9\],AH^[YZ8A)2K"KP?Z.^=U9IA'X
M$FS7Z$Y#F,'1W\XRDDUD3ND[=_[33S^=2BX]=DY];J#%6A6[>IK3OYWF],B]
MP)V>G[K\CD1RZK&SC,NCT*/3FA_X#.;GDQHV9$)_Y*[+?/41GE^#_PCNZ.DG
MLLWZ9QG' !OQZ0A'8KS6]&&Z:0.($]1K^2Z;?&+3#.'N6:9OY.W,N07:L_(%
M*U\\S2V-NL
G(=?H[4W)-OW$7O_
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M$*,P?@8*3T+J8E:N6<2&,=()
P1K@204ZUH*#I@J$QFMI;0]T!.(&LZ$
MD_7!E" "C+@WK;WK\A&X\S4;DW8PHOZ[; 1VU]=M(OY?5K.+,('Z.M9<'L,0
M2B\)UW8>)?SENM5M7I!.M]YM=I;M8H'P R"TTVQ\:;>ZK6:'U*\O2///QL?Z
M]8
R%)/JM*[S%82MBO%I/5EI(3P:/\6-_/SRLUVV3@Y# [N9$)A_NWG=)>WF
M[4V[>YB4;Y;U[9=VYTL=2._>$'#C+O@JL0ODIDWLTI'[GMQ
I( )6"1)\PX7;/HQ<]_7R"8WZ%'G
MZT $L>\:"
V?*=0$" 5F6
2^XQ:-R#D)2(JH2K>MLHV!4[_R:K15EUZ:255#<<98[+@BMG
MSDL5(U^P;+M8^*;D'MZ;(0X_0TI1[D@"00(Y9(+\%0L>N=Q!T4".444.ONB^
M[Q_'?IZ'^48P&O$(=P<(.A'1QO"J6&R9;;-CDN8H]((I*'C9^LEU8+Y?M^M=
MZBXO"#(4[Z]G/>!0_R0R>*R_)H99:#VL0LR^D;?NNH)%4?*_SS">G4;=X\RY
M;15)@PH?("TC#<42N1#\CF5))^80H0J6=9A0_4&ETX"/-Z(;C&>HIP*K?@$1
MF,G 7Q5 =H\ZTM(T*NC?B%O 6%SM7^T(P:J9
2N%M7DEY%Q')/!8. Y\17R&D+ %U>C'JA,!R
MC(+.7+:Y]/8$3GJTNY=B?*T#P4M^:6?.RU9UU2O?[Q%+
;)'D,/+]%K>_A P*F$77YH1*
MJ/"5ZA (_M+'>IP_8 :,>42CT9R?XXV[3K/MJ2?D-T.!''!)8?!=!62"> L
MC$448SE2!@1:J 6&G3_JO<<4@,>HZHZL;2%^*V
:HBU=K#%Y2SNWC^"6V446=(''#-: =0\H/(1E"5YCO342_PCG:"
M:SM)1NA)7JW@KI-=&F53;**C/X&(.!YR^$6%NWGLW&<-L'R29JL$7[EA[H[.
MDF0UM?,]Y>DS=%;(G&,%$'32D8'S]3LJY6^JV$\52331P62FAZ+:G[U]+OF_
M]DBTOZ
7^AXWM6Q'_%D>3]
MZ=/+L3%DP!KB6!J&(@@%QZV37C A/>8%8\3X^!!7 J1B?")][F'FY!&LEB7S
M74#( (PC/HH]27T6Q)$W)1&5/.I/5<^D0] #/FFR Z,>+.STQS .K"O\:?JL
M#Q X&&,_K-=QW,R(R%'$&/G ?":H1UH^](TU'*^;>5.3^WX=B6\0?N7PJOS;
M4'#>+!]7'@0W5\NFE<\_:9%_K\VA/V!H'#X"4Z9^9#QZ7/@#@@)8,";+V$^V
MCJ)[C]7;97TZL'+RT'O020@XB!VV1#; PZ)PEM;"[1B\IY@O)
B=/%NW??/MMS3\4"[
$2 .A F\C$@D"['
^Z6/WF
74NHU\0GM][\X;]T;HEZ"ZEK];W@,GG79
MZ'Y\K38W!.=B'G/PZA _4"$KCIAJ!5PF%4"\TX*K6IQ^P1UEK.;RICBYNG($
M[<8'MN")8'<\@G[@LM1W<,E"'0??GL#&>/V$2X4;Z=J?NVT/OG!$9WOPB[YH
M/I-UIC9S_^F'N4T<%)YZN6_.+]YL$ ;:$FN">13/Y*W==3 G0
T7 \NZ-A*.;H9L",GF#TJT'[D"IJU!O3:83
14[JS+PKP&D[&55
M'.'OO_Q
>M$_58?;9/5-96[RX/*2 QA\7*F*(L:?F.N=0MP6RSCE1K#"#!
M1^:#3CX$$>N)V!FJ34@F[M1AE#D]@%TH<1.*$AA"(+:. +N$7*BCOE*U7YC)
M/CZ)D+-C@"Q^#.!DQ)A")D!VA#O!P\!S4>'K1QU?B!*OA#D779:4"ED%\Y0
ME= :0\[Z@*K28^V)C8- X#'( \\#I]BKEVK>G3MAGWRF7UE? "7D5Z[>PJ.A
MTC.0_WL6QNC!K\P9^L#L8#I;R '84ZA4;2KW8N[IT]@P=%]=("6Y>ACRD"%7
M.-$(N\#G2&'.$%*^
;
MG&&]HE-4?LDDM]!9("$S7K)D27(+ H,5?Z1NF%(BVB8^F/6:Q:- 4-)=$(DV
M?)1*"!"(.]X4$34"7Y_%(H@
K]SIMU337[!'&T#>&7>*@%@3;"*A\",
MZUZ8(0Q@<=#CGEXVZT/V##./?O\2T8:>,JM8!%]3%**?>Q BD?
!&%!_QH<67B,P/C+JIG9_'0@PL;I:&H+W)F3@2CD.UU?Y+R0R=!7#
MH#<_ $^9)3Q,JZHTI19G*-L>DV/&_!69JOB QSA4#0?6@A$N"1=6;_J
70W
';"\089(ZDN@'OL'TBZAL
M1N^JK7%<0_,!1VP-!""9'%\=DLHZU2GRK?E07?N'409DVV;J)387W2R?'$N"
M1A@8062W'MC*8OK$']+<:>(9'N62*%_T_L5,N4KPF'L>R,QA.*Z3PB"4!X90
M6*P+%R^)G%\FNIH_!\DYG5#M3R;1>6D@$/-&V44++^)DU01!+(G'1URJCNCU
MT *"! P_4#4*&(IBI)'@BB@=E:4)WJK@+E14E7B&]$ZG%-T3[YXA?
MS A8"8P**OI7*5_*@IN1&,+7+*(LR$M;LI+3'=[9H_0H6#J$ND;3\Q*TZ"='
MH
K6 [CB(ZF
MJ
^(N0TTT9I
;<"6]RCRX-7?G4<)B(=1C"&-A.IE2@'1
M'_ 9^DEJ(45M(>@;0>P[*+,EOYB)GRXLXL &%K _8H-%+<^Z:#M1@H;P"E$I
MG!T\7*8'=QVDI,Y0YPU5R)^=A%1P:@C 1I)JU;35?/-;):!';TIF]YX2S*O<
MWU#]W_%23VO3K9YX
^IZ8#8[%=3TTG\
M::]2RHJYIZ7CY'C\;+
]
MA9!7&T(T28"@DFN0:@HK8ZN9C2A0<1V8KR3$?(OC"Q8Y@H?X\UXOKCW8Z;WG
M>I4&T
JUY02?7U;4=8:'7=Q3_
=
M27)Q_\.A<:2J0FJG0=VFK>N[N,"'!X&^-;C'AM3KXX(
2[P^BU$U\/J.\''^T)>#FDX^R_3FO_%'(=$CNY*$
B$=^2^W!WI-\4_C"O5#_V)\/AIT.\_'4Q\IQ
MEDMUL)PM;+U=SHZ:)UMO+V^]E--_Q%#]XG9
M"JM< @ VP8 ! !A;FDM,C R-C X,3DN>'-DS51-;]LP#+WG5V@^3_Y(
M&C<.FA18BP(#L@]T+=;;(,M4(M26/$ENTG]?2;&6IED*9*?Y1)/OD7P4I8O+
M35.C)U":2S&+LCB-$ @J*RZ6L^C^[@9/HLOY8'#Q >.'3[<+="UIUX PZ$H!
M,5"A-3
' P\Z%LR$>9?%&5U'R#SWLYGE:#X%W>@\^
MF08:+^534@%W(QS_O;P^!G<&=L9^32*$-)[O/+VO;;E@
]5N:%461^*A=.4\FBBI9P_O@I%6R!64XZ-<[ZQ.L%+!99#<(A^WYU2J(
M;2,!<9!__P1
D/%6^I4!]HFY'
MO+-QQ*M9="7MFQLAY[N__7QPL7V1+28D"6DJ8%QPOV:I_S*$=Z\R1IYUD;S%
MOLG2::B^B;FWWYYE3^XA[Q IJ6E7G\[;M764UCO#S/H;E>Q?J>W_JVOG'=N[
M/!^\ %!+ P04 " I6!A=*Z&Q[B4) !]5 % &%N:2TR,#(V,#@Q
M.5]L86(N>&ULQ9Q=;Z-(%H;O\RMJO3>[TE1,\4W4R:@WTSV*-M,===*:T:Y6
M45$4-FH,49E\_?LML)V *:"JL.F;A-CE\Y[WF(=S<, ??GU9I>")LG629^
XS]&>_7IR
"245S0"#PG
MQ1(42PK^S-F/Y F#FQ07<
P;ONV@V/YE<8:P91@Q)="E40#MD 008P]!UW4-UPJQ
M[V&S"IHFV8^S\D>(UQ1P>]FZ^O-\MBR*A[/Y_/GY^?0E9.EISA9STS"L^6[U
M;+O\I;7^V:I6HR (YM6S;TO7B6@A#XOF?_UQ?4N6=(5ADJT+G)%28)V
KAY3N'ELR&HO#IHPU
MHI99!F66R"VS_'N7V'Q$^@?*MVCG>H#D*KM?#I5C7TV_'"S=.WZ$H,=/N"8S
M.N7-#O4IBZ;:=]^D1J=^_(P/M5OD!4XGV"W>96HII^4#UWQK*U,&ZCF85CK;
M0W
%O_@&;$$I_=[C
(<$BP$=P7;WOT/
*70%WZFX*KHH)/1=?[(R*:O<
$F[=*_Y'M,L2,#-1JNV).
A0DW]AO_F1)P6F[S%>KQRS9C#_K?8Z
QKA30TG!F!)&70ZT"&H%FPR>+AMU;CK7J"-SF3]1]C%<%PR3
M0F(_::P_WDY2R8#_[H3^=YA=1)B\UO[1C#39SB$T4-\SQ O4=XO=)UUO)W>_
M\0%H_W :V!ABA&P8F22,#6IZU)(>^H4*1SZFOGU^MQ$%7!64LO)'5G%=AK$9
M[58-'V6C2ACUFM'"21QQ,JQZ#=7QZE^HCMD-H^7P0WF&9=B[\F2
\).AN.PM3J3$JO5P?S(0T5EN,\I7NRSZ#LNQ'[@PYB$?LQ[GTN1
M(
+WD@1A.KSAD+_^FK_MH6+8#,44.))Y!+>+[)HI\632$"D=&9*,)MJ*@
M4@5<5AX6<5V&H1GM5@T>9:-*&/6:T<))''$RK'H-U?'J7SAZ)+Q:KQ\IZQD,
M78_"T'
_:XCLM-DS2G:_1K=[WN&7JXA'3N+MI]WBSZG-P(:AYV%(73^,(B>.
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M!HC00)T,\0+=0>XJ(SE[R%GUD<=M@0MZF3]F!7N]S*/V7&?S+1\3Z&#'
3G2QV+BDU2T9W6<+EO8]1@^19L\J%RWX9H
MH&RMT>V<'Z.(OVWK"LJO[(;E3PE/=!\D9,4P($%Y
U^_O7;3&U@_$MB;
M?%W@]#_)@W#"#4V(?2^$Q(YL.W0MSR.V%JX-F8EAW6@#+JXUS H+I0BJMOUQ
MF,HZUX=4:&P\HLVP/P=0H;5./,6K1\)YR3>_LKO\.6M=JQ:Y, Q=$P9A:'O$
M()9O$2TRWS4FQK(4+EM(*:W)9*T^BD#JN1Y'HY1A?13;EL9S6(OY
I-L765B!+<;H-0&7S/=UMBH
MDR*(NN['H2AM7!]'D;'Q0#:B_APD1<8ZH10NUK^)]HZ_M'5.&8
J!IOMJ!4'ZC6]6$#W?A4*]HKR+_+@X
MV3V2;+ZM\N+D_U!+ P04 " I6!A=NGP5A=4% #+, % &%N:2TR
M,#(V,#@Q.5]P
&ULU9K;;MLX$(;O\Q1:[^TR)JD3&30ILMYT$6S:!DF*
M%GM3\#"TA
CKZ=/<.L=';LZ.C-[\A].7/FROOKUS=SR$KO8D%48+V
MEDDY\\H9>)]S^RUY$-YU*DJ3VSE"9_6T2;YXM,ET5GH4TV@S;/.K/<%$8&(B
MAKC@"L7$A.[(*!1*8QAF04A,\,?TA @?8P,*1: Y"J3B2(B8H"B*<.1+P6)!
MZXNF2?;MI/HC10&>"R\KZJ^GHUE9+D[&X^5R>;R2-CW.[71,,?;'F]&CI^&K
MQOBE7X\FG/-Q_>OWH46R:Z"[+!E_>7]UJV8P%RC)BE)DJC)0)"=%??(J5Z*L
M5?]?O[Q71U3?T&88JDXA0I%/CE>%'IT=>=Y:#ING< /&JSX_W5Q^-RFRY%CE
M\W%U?CS)'0?.PWI&^;B TU&1S!
%<[56O !U/,T?QN["3GD:5@>5
M#&$M0
1K/K?)R
MJ\&Z&K$Q)ZQZD=(FG4\CQ@MAW860FB6IWLPV-I_WD:LR[T&Y=5J
DJ)]0C^\CX-=@DUQ>9_LN5UNT B!;NR'U5.%9,:D/"*.HE
M]2_,MF* #I^!_;4\, P769F4CS
MHY RB;D*"'2\Z[
'M\^SF6>-MJMF"&I.$6*
('W(K<7[R!W/07*S43V11V]=J-*UK25R$R1K(@I &0@/=R
MXS^WVHZ! 7
#N8D^R#@N.RZ*X!_N36/S0R:,@0K&4CG)"G#R](M+PH!TH ^XT
M]BKQ(+J-%W.P4U<-_[;YLIRYX!8B>VP\:2$^DA0HBC &X@L9\K#;VW(_,=[N
MQ:G!]QN["SL(/B9.,BO22X?XZA]H!,")VT!#B!$-B3)$:.U6T#V0L66V'1,#
M;D%V%_/ -)R[>J>KFO
?3\[^@]02P,$% @ *5@874X);]H-$0
M
&5X>#DY,2YH=&WM6VMSW+:2_;Z_ FO7
M^MI5,V-)ENSH$5
JFM[2!!H]./TZ09RDC=E\?(D5S)]^1\G_SF=BM
JN5+)WM[>@3R0AWO[AX?_L_L
MGV*X_\8UJT+]^*#4U317M/[1L^=U<[S4:9,?[>[L_->#T;A&?6FFLM"+ZHBE
MQ=O,8&_A=6(*8X\>[O#_CNG--).E+E9'__B@2^7$A5J*]Z:4U3\F3EF=^3%.
M_TMA,:S+/Y=>D!>8HM"5BH+M[I$T9U]R/=>-.#R<[9X\I?%Q.]VF7I[H
70 66Z4;70BB[!?
MWKI_'=5SL%=_V:3-@9826$S9H"88R[X<"_V7??4-)CFU6A8PA*S<])8U]K_)
M&J<7Y^(RE[:4B6I96TZ
/$+ZJR*_&S<6INVR07C1$_&6E383+Q6EN5
M-,8Z\7]$'WM1'SS/D6ZP1C+2T/YUZ^,/>[NYQU HC@6NLJA9-KBHGYJP1
M";5!E3))5*$L8,*)QD*.S$"UC3:5P+=&2%$@Y@D^WDNKH$2GI%, C[*6U4J$
MM?XDC?[)>ONJEB[?GU^\.OOPV\5$7,Q^G4W$:;MH'
43
M>&0J5\*JVEA"9AHNTU2SPN&D&QQ8PZ\W.+'*,OQ+WZ@H^.ZA%WPFWMG98(JY
MA?6<, 7\6Q'K)3$UY@J,19"P/#D'/AKL9J(.64*Y9Q(U8TJ3,V^(ZM49+J2
M5:*$^E)#W8K^*1-K,))V,->F'FE%.)9R=CO4[HOYR7'W=HX_8Q^6MI5H-H
; U9L-H
R3JH)LYP5=JH*_S75)/SMM35B\
MPIAKLL*2](?79*,$[F#UO.5]=R;):9TJ*=I4I;/[[J@$+[GTX08WD0O%!FF4
M+"?\$"HIE4VP'LR160ESMDG30GFD%8Y267 ,NURIAC4GK\D"I9(5+)"UA:@
MU]B6JLFE"'C4C2E8;>)&RPZIL,8F]^B=7>ITC$*="W^ ("-30]0J@9$4^:,D
M+S3PALRT5
*4_VK7*M,G/%V*6?\
MEF4Z04( P+R%%V26I/Q)&RC"RII1'-3YDWA,VU>V0$Z"]]1R8>CQ$P'CPY/>
M(94AY1Q,Q!+?*8HH,F+A#+M5.?
&-AKE_;@B=Y1@9Z0\)+&V?%
M=_T6+JUR.HTH])4-7:BV!!0":_N]^"P-7Q)U.P>-PIJP+@(?9F^1QQ*?TR+N
MW%L;7UI-"<;$34X0/U#BWL[N 3TE/4[6\O\2NNOU] E:VJC*JY@V!IH\G<\_
M:36P[KS5A?^H".0E:(QYX(MC.%J7A]8FG B'@00T&YD'S:-09I*,()X(7KT@
MDWR%D[Q[]/#9#\>GF!B4!ANE9XH27L0-S,& U^.E!Q._+?$)#X"/<,2/58H-
M4Z:@;*2LRW7M475A35NS<(6B] .=$UH@3Z-2]0 A$Y].:69=(04RXX;':
C019F+1?(E M9S<29M(6&), ?3EO 265]&-2TZW[UO4CD9 ,:<0G.
M9VB*"8: "B+",!P^3I%OIK]@4QP8X)RY.$4\@Z-547_WU]G'?LQ( .9:L6%.
MTQOM#)"B Q9Z^K&"_UBH=D5/+E55N55Q@_0FQ5N=P2=]G#O!6P=^=8GTTIJ%
ME248&1S=%"GEHI]F5S.RQ1EH@BD)$3G8:*'/H+L-1+E*
V!V6.!K])P3)5L6(K+751
MX)M24K;V :,ZF!M0)&L*%:K=+@)C1+Q7 ^QXO88O'A=_JXG&4A2/4LQ2_ I+
MJU5\#P3X8^9;ZPAQ#ZPV'A6.K"J83F_MBH6FT4[_B9P[HFJW/]DJQ/#/W,:9
MD>/5=(Z"X7HJ,Q3L1[)8RI5[\(>:=W>L^1UP)!1:7 KHJE6H%@(C/4>&K#P?
MAM->"W)@+N.\?Z; 2D)^[[8$0I1!8VTEYX4:EQ>^T"9'K\'!43C#&QFJN9AA
MIXTR^#JH4IEN/++0BKIR)+K/)ZD"%1_6W&Y$K*BTZGV^SUU<%MPCOKJEDS
(*3C>AR*7ZH]3.!8X0?/6*
MW ]0= ET\"3CO*2& #U[2^5WK,#FJTB7\&I"<-AFDLI!_LEE?%
XNW2&;#JF FALD V\M,TCH(#4&I3,=.:3K7N@;(S/$!$K4$
M\6ARD*E%SEL;E8"1X1'1U #C4MIKU5#:P ZHX9&BDN6JC-MEP"9N8$&/B-BB
MA+&)0=H
E:BP7_]W&?]+6ZA;?5/P ECH\9H%^1AQ:2O'KPA10HP4F
M0F8F#:]]/#:0?0(1 OC#C.I+ M;J.2LM\Q'L83J7I)J1^OV:S >HLP<*F?:K
MHB@"\C#/0Q4?2\\)JF_ ?-=-V^+K6?:G^WK>-+5C?W[T
M[&9PJ/L0LYNQYHUO'$S?&L-=@RMJQS%/OP
D*Q\#Y&%AD>E
MR@<$(A!L@>,H57!#[H<,?,<3-,TDC!(,2!79B\L;Y[MKH:LR+8)R!NO0;"'N
M0ILH4FU4HC=
# 35\SB^[E]?<05
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M9K9HSZL6
+\VJ\@K44J1)3^K(KM^QT:+B3D?JMZ
M[.6WY_5-V+
4S"7\W 6-C.NREBWEVT._Q
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M%!P,(:/066C=<">:D85[ ))/IX9G49B7>EFT99(ITTW8P5
!D
MX<6C6>DGE@M*\'A %O!M!Q9S="B\H8N- A:I4L'():5LRW,V-*V7#%4?0L+W
M*[2S;1V.ESUM#.H-=>PW62(PJ8I2!#E/8ES( !TLBH+N'F#"2-*$'DT.-%,I
MNREH5K50\+>:?(\/[U4\-HYN4[6QH](/BWG=RF7GYU"'],W(M1(>/F-5&DIR
MNDQ0AW_W6:F;XR]2FN\-^?BDCUAV%4Y , ]= 02%<::U[(C:IIS[?$O,8E_C
M,M6KPG?"0B3&::_5Z@]&S6C/F#"3NJ!L0%
V*S&VA0Z\?X?#F@X^ CE@%QT]%T-II]0[YY<@0M#)U[;=B'.*B9@W! ^
M38'RF@N-R.B\78
I($W\M/@U"@!54)4UJZZ:RJ]R=5=&O:D&ZDV%ZDIB3XG
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M*-AV+%]UE?G=4R9@AD[7(":8R5#6C*<2\
U]'W%_>!;'X>[+Z8OGNWC_S^\^*[RG'EY_OXS2[;;[-K;[='#Y_O'FT\K
M[VW\O:-[3M\_^$[MPC3B,A9&]\&Y]W;WIL]W=J:[^X?[WU>@[^;=\&7OTV2=
MR'/OB3MOEOB*^P+=I9AOO.USOTX$GOK_YO4I_[>V_P902P$"% ,4 " I
M6!A=<.\LA)$2 '= $ @ $ 86YI+3(P,C8P.#$Y
M+FAT;5!+ 0(4 Q0 ( "E8&%WIV0JK7 ( -L& 0 "
M ;\2 !A;FDM,C R-C X,3DN>'-D4$L! A0#% @ *5@872NAL>XE"0
M?50 !0 ( !214 &%N:2TR,#(V,#@Q.5]L86(N>&UL4$L!
M A0#% @ *5@87;I\%875!0 RS !0 ( !H!X &%N
M:2TR,#(V,#@Q.5]P
&UL4$L! A0#% @ *5@874X);]H-$0
XML
16
ani-20260819_htm.xml
IDEA: XBRL DOCUMENT
0001023024
2026-08-19
2026-08-19
0001023024
false
8-K
2026-08-19
ANI PHARMACEUTICALS, INC.
DE
001-31812
58-2301143
104 Carnegie Center Drive, Suite 300
Princeton
NJ
08540
609
759-1810
Common Stock
ANIP
NASDAQ
false
false
false
false
false